A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : ABA / abatacept

[Related PubMed/MEDLINE]
Total Number of Papers: 68
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   ABA  (>> Co-occurring Abbreviation)
Long Form:   abatacept
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A Network Meta-Analysis to Compare Effectiveness of Baricitinib and Other Treatments in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate. ACR, ADA, BARI, IFX, IR, JAK, MTX, NMA, OR, RCTs, RTX, TCZ
2020 Abatacept induced long-term non-progressive reduction in gamma-globulins and autoantibodies: dissociation from disease activity control. anti-MCV, FLC, RA, RF, TGG, TNFi
2020 Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network. bDMARD, CRP, OR, ORA, RA
2020 Comparative efficacy and safety of current therapies for early rheumatoid arthritis: a systematic literature review and network meta-analysis. MTX, NMA, RCTs, SLR
2020 Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry. bDMARDs, RA, TCZ, TNFi
2020 Does Abatacept Increase Postoperative Adverse Events in Rheumatoid Arthritis Compared with Conventional Synthetic Disease-modifying Drugs? AE, csDMARD, RA
2020 Factors influencing the choice of biologic therapy following Rituximab in patients with rheumatoid arthritis: A retrospective study using propensity score. DMARDs, RA, RTX, TCZ, TNFi
2020 Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis. bDMARD, IFN, RA, RT-qPCR
2020 Infectious adverse events in children with Juvenile Idiopathic Arthritis treated with Biological Agents in a real-life setting: Data from the JIRcohorte. ANA, CAN, ENT, GOL, IAE, JIA, TCZ
10  2020 Safety and effectiveness of abatacept in systemic sclerosis: The EUSTAR experience. mRSS, SSc
11  2020 Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study. DMARDs, FVC, HRCT, ILD, RA
12  2020 Systematic Review of the Impact of Drugs on Diffuse Interstitial Lung Disease Associated with Rheumatoid Arthritis. ILD, LEF, MTX, RA, RTX
13  2020 The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. bDMARDs, RTX, TCZ, TNFis
14  2020 [Survival of bDMARDs in bionaive patients with rheumatoid arthritis: data from a retrospective 12-month follow-up]. bDMARDs, RA, RTM
15  2019 Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis. bDMARD, CHF, MI, NMA, PAD, RCT, RTX, TCZ, TNFi
16  2019 Clinical effectiveness and long-term retention of abatacept in elderly rheumatoid arthritis patients: Results from a multicenter registry system. MTX, RA
17  2019 Comparative Effectiveness of Certolizumab Pegol, Abatacept, and Biosimilar Infliximab in Patients With Rheumatoid Arthritis Treated in Routine Care: Observational Data From the Danish DANBIO Registry Emulating a Randomized Trial. CZP, DAS28, DMARDs, RA
18  2019 Predictive factors for structural remission using abatacept: Results from the ABROAD study. bDMARD, mTSS, OR, RA, St-REM
19  2019 Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance. DAS28-CRP
20  2019 Subcutaneous abatacept in rheumatoid arthritis: A real-life experience. RA, RF, s.c
21  2018 Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients. ILD, RA
22  2018 Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease. CV, CVD, PS, RA, TNFi
23  2018 Concomitant use of intravenous methylprednisolone to increase retention rate of abatacept in rheumatoid arthritis. IVMP, RA
24  2018 Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-alpha Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study. CDAI, RA, TNFi
25  2018 Efficacy and tolerability of abatacept treatment: results of 12 months observation. AE, RA
26  2018 Immunotherapy of systemic sclerosis. Beli, CYP, IVIG, MMF, MTX, RTX, SSc, TCZ
27  2018 Liver safety of non-tumour necrosis factor inhibitors in rheumatic patients with past hepatitis B virus infection: an observational, controlled, long-term study. HBV, non-TNFi, RTX, TCZ
28  2018 Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial. AE, DB, IR, LTE, MTX, RA, s.c
29  2017 Biologic Disease-modifying Antirheumatic Drug (bDMARD)-induced Neutropenia: A Registry from a Retrospective Cohort of Patients with Rheumatic Diseases Treated with 3 Classes of Intravenous bDMARD. bDMARD, IFX, MTX, RA, TCZ
30  2017 Detailed Analysis of the Articular Domain in Patients with Primary Sjogren Syndrome. CRP, ESR, ESSDAI, pSS, RTX
31  2017 Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients-A longitudinal analysis. MTX, RTX, TCZ, TNFi
32  2017 Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. AE, bDMARD, LORHEN, MTX, RA, TCZ, TNFi
33  2017 Pre-silencing of genes involved in the electron transport chain (ETC) pathway is associated with responsiveness to abatacept in rheumatoid arthritis. ETC, qRT, RA
34  2017 Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry. AOR
35  2017 Safety profile of biological therapies for treating rheumatoid arthritis. RTX, TCZ, TNFi
36  2016 Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry. csDMARD
37  2016 Body mass index and response to abatacept in rheumatoid arthritis. BMI, RA, TNF-alpha
38  2016 Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis. ACPA, HRs, RA, RF
39  2016 Comparable Efficacy of Abatacept Used as First-line or Second-line Biological Agent for Severe Juvenile Idiopathic Arthritis-related Uveitis. anti-TNF, JIA
40  2016 Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry. CDAI, mHAQ, RA, TCA, TNFi
41  2016 Differences in Predictive Factors for Sustained Clinical Remission with Abatacept Between Younger and Elderly Patients with Biologic-naive Rheumatoid Arthritis: Results from the ABROAD Study. ACPA, HAQ-DI, RA
42  2016 Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database. ADA, bDMARDs, ETN, PDC, RA
43  2016 Predictive factors of abatacept therapy discontinuation in patients with rheumatoid arthritis. RA, TDEM
44  2016 Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry. ORA, RA
45  2016 Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report. HBV, RA
46  2016 Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis. RTX, TCZ, TNFi
47  2016 Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis. ABA/MTX, AVERT, CRP, DAS, RA
48  2016 Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. ACPA, CV, ETN, IFX, ITABIO, LTBI, MoAb anti-TNFs, PsA, RA, RF, SpA, TCZ, UTK
49  2015 Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis. JIA, MIWGUC
50  2015 Longterm efficacy and safety of abatacept in patients with rheumatoid arthritis treated in routine clinical practice: effect of concomitant methotrexate after 24 weeks. LDA, MTX, RA
51  2015 Subcutaneous abatacept in rheumatoid arthritis: current update. i.v, RA, s.c
52  2015 Switching from intravenous to subcutaneous formulation of abatacept: a single-center Italian experience on efficacy and safety. s.c
53  2015 The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. anti-TNF, CDAI, mACR, mHAQ, PS, RA
54  2015 The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries. bDMARDs, GDP, RA
55  2015 Validation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) for the Hand and Foot in a Randomized Placebo-controlled Trial. GRI, ICC, OMERACT, PsAMRIS
56  2014 Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. ACPA, FLC, Ig, RA, RF
57  2014 Economical impact associated with a biological therapy prioritization protocol in patients with rheumatoid arthritis in the Hospital of Sagunto. ADA, ETN, IFX, RA, TCZ
58  2014 Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. AZA, HCQ, ILD, LEF, MTX, nbDMARDs, RA, RTX, SSZ, TCZ, TNFi
59  2014 Longterm safety, efficacy, and inhibition of structural damage progression over 5 years of treatment with abatacept in patients with rheumatoid arthritis in the abatacept in inadequate responders to methotrexate trial. AIM, DAS28-CRP, LTE, MTX, RA
60  2014 Reduction of peripheral blood T cells producing IFN-gamma and IL-17 after therapy with abatacept for rheumatoid arthritis. IFN-gamma, IL-17, RA, Treg
61  2014 Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial. DB, LTE, RA, s.c
62  2014 Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-alpha (TNF-alpha) targeted biologics and recently licensed TNF-alpha inhibitors: data from clinical trials and national registries. ANK, CTP, GOL, IL-1, RA, RTX, TB, TCZ, TNF, TNF-alpha
63  2013 Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. DMARDs, FI, GMTs, MTX, RA, RA-ABA
64  2012 Cost-effectiveness modelling of sequential biologic strategies for the treatment of moderate to severe rheumatoid arthritis in Finland. ADA, ETA, INF, LDAS, MHDAS, RA, RS, RTX
65  2012 Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry. EULAR, ORA
66  2011 Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. AIR, OR, ORA, RATIO, RTX
67  2011 [Efficacy and safety of abatacept in patients with rheumatoid arthritis and no prior treatment with biologics]. IFB, MTX
68  2008 Abatacept in difficult-to-treat juvenile idiopathic arthritis. DMARDs, JIA